Q32 Bio (QTTB) News Today $32.95 -2.68 (-7.52%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Positive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price TargetNovember 11, 2024 | markets.businessinsider.comQ32 Bio Advances Clinical Trials Amidst Financial ChallengesNovember 9, 2024 | markets.businessinsider.comQ32 Bio Inc Grapples with Internal Control Challenges Amid Compliance CostsNovember 9, 2024 | markets.businessinsider.comQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comPositive Outlook for Q32 Bio: Buy Recommendation Supported by Promising Pipeline and De-risked Lead CandidateNovember 6, 2024 | markets.businessinsider.comQ32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation ConferenceNovember 5, 2024 | prnewswire.comQ32 Bio Inc. (NASDAQ:QTTB) Given Average Rating of "Buy" by BrokeragesQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating onOctober 31, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Shares Down 3.6% - Time to Sell?Q32 Bio (NASDAQ:QTTB) Trading Down 3.6% - Here's What HappenedOctober 28, 2024 | marketbeat.comRaymond James Initiates Coverage of Q32 Bio (QTTB) with Strong Buy RecommendationOctober 26, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Trading Up 5% - Should You Buy?Q32 Bio (NASDAQ:QTTB) Trading Up 5% - What's Next?October 25, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Receives New Coverage from Analysts at Raymond JamesRaymond James started coverage on Q32 Bio in a research note on Thursday. They set a "strong-buy" rating and a $90.00 price objective for the company.October 24, 2024 | marketbeat.comOppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical OutlookOctober 16, 2024 | finance.yahoo.comQ32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024October 14, 2024 | prnewswire.comRenaissance Technologies LLC Takes $265,000 Position in Q32 Bio Inc. (NASDAQ:QTTB)Renaissance Technologies LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,764 shares of the company's stock, valuedOctober 13, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Shares Up 4.8% - What's Next?Q32 Bio (NASDAQ:QTTB) Shares Up 4.8% - Here's What HappenedOctober 8, 2024 | marketbeat.comQ32 Bio Inc. (NASDAQ:QTTB) Given Consensus Rating of "Buy" by BrokeragesQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has earned an average rating of "Buy" from the six analysts that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The averageOctober 6, 2024 | marketbeat.comEnsign Peak Advisors Inc Purchases 38,750 Shares of Q32 Bio Inc. (NASDAQ:QTTB)Ensign Peak Advisors Inc increased its position in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) by 150.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,481 shares of the company's stock after acquiring an additional 38,7September 29, 2024 | marketbeat.comBank of New York Mellon Corp Invests $315,000 in Q32 Bio Inc. (NASDAQ:QTTB)Bank of New York Mellon Corp bought a new stake in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 17,569 shares of the company's stock, valued at approximately $315,000. Bank of NSeptember 26, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 3.7%Q32 Bio (NASDAQ:QTTB) Trading Down 3.7%September 23, 2024 | marketbeat.comQ32 BIO INC. O.N. (DB0.BE)September 20, 2024 | nz.finance.yahoo.comHarvard Management Co. Inc. Makes New Investment in Q32 Bio Inc. (NASDAQ:QTTB)Harvard Management Co. Inc. purchased a new stake in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 162,965 shares of the company's stock, valued at approximately $2,September 16, 2024 | marketbeat.comQ32 Bio Inc. (DB0.F)September 13, 2024 | uk.finance.yahoo.comWells Fargo Initiates Coverage of Q32 Bio (QTTB) with Overweight RecommendationSeptember 11, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Reaches New 1-Year High at $52.64Q32 Bio (NASDAQ:QTTB) Reaches New 1-Year High at $52.64September 11, 2024 | marketbeat.comQ32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Recommendation of "Buy" from AnalystsShares of Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) have earned an average rating of "Buy" from the six analysts that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendationSeptember 11, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Research Coverage Started at Wells Fargo & CompanyWells Fargo & Company started coverage on shares of Q32 Bio in a research report on Wednesday. They set an "overweight" rating and a $95.00 target price for the company.September 11, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading 3.3% Higher Q32 Bio (NASDAQ:QTTB) Shares Up 3.3%September 6, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Sets New 52-Week High at $45.00Q32 Bio (NASDAQ:QTTB) Hits New 1-Year High at $45.00September 5, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Sets New 52-Week High at $43.48Q32 Bio (NASDAQ:QTTB) Reaches New 52-Week High at $43.48August 30, 2024 | marketbeat.comQ32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097August 29, 2024 | seekingalpha.comQ32 Bio to Participate in Upcoming September Investor ConferencesAugust 29, 2024 | prnewswire.comPiper Sandler Sticks to Their Buy Rating for Q32 Bio (QTTB)August 23, 2024 | markets.businessinsider.comVanguard Group Inc. Makes New Investment in Q32 Bio Inc. (NASDAQ:QTTB)Vanguard Group Inc. purchased a new position in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 107,752 shares of the company's stock, valued at approximately $1,8August 20, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)August 19, 2024 | markets.businessinsider.comQ32 Bio Inc QTTBAugust 10, 2024 | morningstar.comQTTB Stock Earnings: Q32 Bio Misses EPS for Q2 2024August 8, 2024 | investorplace.comQ32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | finanznachrichten.deBuy Rating on Q32 Bio: Promising Clinical Trials and Market Potential for BempikibartJuly 27, 2024 | markets.businessinsider.comQ32 Bio (NASDAQ:QTTB) Reaches New 1-Year High at $42.98Q32 Bio (NASDAQ:QTTB) Reaches New 52-Week High at $42.98July 25, 2024 | marketbeat.comQ32 Bio Rings the Closing BellJuly 23, 2024 | nasdaq.comQTTB Q32 Bio Inc.July 23, 2024 | seekingalpha.com2,092,106 Shares in Q32 Bio Inc. (NASDAQ:QTTB) Purchased by Atlas Venture Life Science Advisors LLCAtlas Venture Life Science Advisors LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,092,106 shares of the company's stock, valuJuly 11, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Shares Up 0.9%Q32 Bio (NASDAQ:QTTB) Trading Up 0.9%July 11, 2024 | marketbeat.comQ32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic DermatitisJuly 9, 2024 | prnewswire.comQ32 Bio Joins Russell 3000® IndexJuly 1, 2024 | prnewswire.comQ32 Bio (NASDAQ:QTTB) Research Coverage Started at GuggenheimGuggenheim started coverage on Q32 Bio in a research report on Monday. They issued a "buy" rating and a $100.00 price target for the company.June 17, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Up 1.4%Q32 Bio (NASDAQ:QTTB) Trading Up 1.4%June 14, 2024 | marketbeat.comLeerink Partners Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationMay 22, 2024 | msn.comBuy Rating Justified by Q32 Bio’s Promising Pipeline and Market PotentialMay 21, 2024 | markets.businessinsider.comQ32 Bio (NASDAQ:QTTB) Earns Outperform Rating from Analysts at SVB LeerinkSVB Leerink initiated coverage on shares of Q32 Bio in a report on Tuesday. They set an "outperform" rating and a $54.00 price target for the company.May 21, 2024 | marketbeat.com Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. QTTB Media Mentions By Week QTTB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QTTB News Sentiment▼0.030.56▲Average Medical News Sentiment QTTB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QTTB Articles This Week▼31▲QTTB Articles Average Week Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Harmony Biosciences News Today Nurix Therapeutics News Today Disc Medicine News Today Galapagos News Today Tarsus Pharmaceuticals News Today Arvinas News Today Immunocore News Today Spyre Therapeutics News Today Ocular Therapeutix News Today Xencor News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QTTB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QTTB Stock Alerts